Department of Bioethics, Clinical Center, National Institutes of Health, Bldg 10, Room 1C118, Bethesda, MD 20892-1156, USA.
Psychosom Med. 2011 Sep;73(7):598-603. doi: 10.1097/PSY.0b013e3182294a50. Epub 2011 Aug 23.
Negative expectations deriving from the clinical encounter can produce negative outcomes, known as nocebo effects. Specifically, research on the nocebo effect indicates that information disclosure about potential side effects can itself contribute to producing adverse effects. Neurobiological processes play a role in the nocebo effect, and this article provides a selective review of mechanistic research on the nocebo effect. Comparatively little attention has been directed to clinical studies and their implications for daily clinical practice. The nocebo response is influenced by the content and the way information is presented to patients in clinical trials in both the placebo and active treatment conditions. Nocebo effects adversely influence quality of life and therapy adherence, emphasizing the need for minimizing these responses to the extent possible. Evidence further indicates that the informed consent process in clinical trials may induce nocebo effects. This article concludes with ethical directions for future patient-oriented research and routine practice.
负面预期源于临床接触可能产生负面结果,被称为“反安慰剂效应”。具体而言,关于反安慰剂效应的研究表明,有关潜在副作用的信息披露本身可能导致不良影响。神经生物学过程在反安慰剂效应中起作用,本文对反安慰剂效应的机制研究进行了选择性综述。相对较少关注临床研究及其对日常临床实践的影响。反安慰剂反应受到临床试验中信息呈现内容和方式的影响,无论是在安慰剂还是活性治疗条件下都是如此。反安慰剂效应会对生活质量和治疗依从性产生不利影响,强调需要尽可能减少这些反应。进一步的证据表明,临床试验中的知情同意过程可能会引发反安慰剂效应。本文最后为未来以患者为中心的研究和常规实践提出了伦理方向。